DRUP trial
A legfontosabb adatok
- Ki végzi
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
- Hol
- 's-Gravenhage, Alkmaar, Almelo, Amersfoort, Amsterdam, Apeldoorn, Arnhem, Breda, Delft, Deventer, Drachten, Ede Gld, Eindhoven, Gorinchem, Groningen, Heerlen, Hilversum, Hoofddorp, Hoogeveen, Leeuwarden, Leiden, Leidschendam, Maastricht, Nijmegen, Roosendaal, Rotterdam, Schiedam, Tilburg, Utrecht, Venlo és Zwolle (Hollandia)Mind a 36 helyszín megnézése
- Állapot
- Toboroz
- Fázis
- 2. fázis
- Résztvevők
- 3000 fő, tervezett
- Kezdés
- 2016. júl. 25.
- Várható befejezés
- 2030. dec. 31.
- A vizsgálat típusa
- Beavatkozással járó, 30 csoport
- A regiszteradat frissítve
- 2026. augusztus 20.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
A vizsgálat olyan felnőtteket keres, akiknek előrehaladott szolid daganatuk, myeloma multiplexük, non-Hodgkin-limfómájuk vagy T-sejtes prolimfocitás leukémiájuk van, és a daganatban olyan gén- vagy fehérjeváltozás található, amelyre egy engedélyezett célzott gyógyszer hat.
- Életkor
- Felnőttek, 18 évnél idősebbek
- Nem
- Nemtől függetlenül bárki részt vehet
- A betegség stádiuma
- Lokálisan előrehaladott vagy áttétes daganat, amely a hagyományos kezelés után tovább nőtt vagy tüneteket okoz, vagy amelyre nincs hagyományos kezelés; a betegségnek mérhetőnek kell lennie
- Korábbi kezelés
- A hagyományos daganatellenes kezelésnek már meg kellett történnie, vagy nincs ilyen kezelés; a kezdés előtt legalább két hétig nem lehet más daganatellenes kezelés
- Biomarker vagy leletérték
- A daganatból végzett vizsgálatnak (például FISH, PCR, NGS, IHC vagy RNS-szekvenálás) olyan gén- vagy fehérjeváltozást kell kimutatnia, amelyre a vizsgálatban szereplő engedélyezett célzott gyógyszer hat
A részvétel fő kizáró okai
- A korábbi kezelés 2-es fokozatnál súlyosabb mellékhatása (a hajhullás és a 2-es fokozatú idegkárosodás kivételével)
- Bármilyen más daganatellenes kezelés folyamatban
- Terhesség vagy szoptatás
- Agyi áttétek (kivéve a korábban kezelt, stabil állapotú, szteroid nélküli eseteket)
- Súlyos szívbetegség, vagy szélütés vagy szívinfarktus az elmúlt 3 hónapban
A regiszter feltételei, szó szerint
Mind a 18 feltétel megnézéseKevesebb
Ki vehet részt
- Adult (age >18 years) patient with a histologically-proven locally advanced or metastatic solid tumor, multiple myeloma, non-Hodgkin lymphoma or T-cell prolymphocytic leukemia with symptomatic or radiological disease progression after standard anti-cancer treatment or for whom no such treatment is available or indicated. For patients with a primary brain tumor: Histologically confirmed recurrent or de novo primary brain tumor, with unequivocal progression after prior therapy, at least 3 months after radiotherapy (either first line chemo-radiotherapy or re-irradiation), and with stable or decreasing dosage of steroids for at least 7 days prior to the baseline MRI scan
- Because of the risks of drug treatment to the developing foetus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for four months following completion of study therapy. Male patients should avoid impregnating a female partner. Male patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, or completely abstain from sexual intercourse
- ECOG performance status 0-2
- Patients must have acceptable organ function as defined below. However, specific inclusion/exclusion criteria specified in the drug-specific study manual will take precedence: a. Absolute neutrophil count ≥ 1.5 x 109/l b. Hemoglobin > 5.6 mmol/l c. Platelets > 75 x 109/l d. Total bilirubin < 2 x ULN e. AST (SGOT) and ALT (SGPT) < 2.5 x institutional ULN (or < 5 x ULN in patients with known hepatic metastases) f. Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 50 mL/min/1.73 m2
- Patients must have objectively measurable disease (by physical or radiographic examination, according to RECIST v1.1 for patients with solid tumors, or according to IMWG, Lugano, RANO or GCIG criteria, resp., for patients with multiple myeloma, non-Hodgkin lymphoma, and T-cell prolymphocytic leukemia, primary brain tumors or ovarian cancer in case of CA125-based evaluation
- Results must be available from a tumor genomic or protein expression test. Eligible tests may include any of the following technologies: fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), comparative genomic hybridization (CGH), next generation sequencing (NGS), immunohistochemistry (IHC) or RNA sequencing (RNAseq). The test may have been performed on the primary tumor or a metastatic deposit, in a diagnostic laboratory or within the context of another CPCT study, and must reveal a potentially actionable variant as defined in Section 5. The test results (full pathology or molecular diagnostics report) must be uploaded in the eCRF
- Patients must have a tumor profile for which treatment with one of the FDA and / or EMA approved (or under revision for approval) targeted anti-cancer drugs included in this study has potential clinical benefit based on preclinical data or clinical information
- A new (obtained ≤2 months before inclusion, and without any type of anti-cancer therapy within those ≤2 months) fresh frozen tumor biopsy specimen for extensive biomarker testing is mandatory before the start of treatment with a targeted agent included in the protocol. Alternatively, fresh frozen tumor tissue acquired in the context of a standard care procedure may be used, provided that no systemic anti-cancer treatment was given between the procedure and start of study treatment within DRUP. Exceptions are made for: a) patients with a primary brain tumor or other tumor types with only intracerebral lesions, only if the mandatory DRUP pre-treatment biopsy for biomarker analysis cannot safely be obtained; b) In case WGS is performed on tumor tissue outside the context of a clinical trial before inclusion, and without any type of anti-cancer therapy between the collection of tissue and inclusion in DRUP, this can replace the DRUP pre-treatment biopsy; c) patients that underwent an allogeneic hematopoietic stem cell transplantation prior to study enrollment, since this will prevent a correct WGS analysis due to a mismatch between the biopsy specimen and the required blood sample
- Ability to understand and the willingness to sign a written informed consent document
- For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome
Ki nem vehet részt
- Patient is receiving any other anti-cancer therapy (cytotoxic, biologic, radiation, or hormonal other than for replacement). Required wash out period prior to starting study treatment is at least two weeks. An exception is made for patients suffering from CRPC are allowed to continue androgen deprivation therapy
- Patients with brain metastases. Patients with previously treated brain metastases are eligible, provided that the patient has not experienced a seizure or had a clinically significant change in neurological status within the 3 months prior to registration. All patients with previously treated brain metastases must be stable for at least 1 month after completion of treatment and off steroid treatment prior to study enrollment. Specific exclusion criteria for patients with primary brain tumors: a. Patients who require anti-convulsant therapy must be taking non-enzyme inducing antiepileptic drugs (non-EIAED). EIAED are prohibited. Patients previously on EIAED must be switched to non-EIAED at least 2 weeks prior to randomization. b. No radiotherapy within the three months prior to the diagnosis of progression. c. No radiotherapy with a dose over 65 Gy, stereotactic radiosurgery or brachytherapy unless the recurrence is histologically proven
- Patients with stroke (including TIA) or acute myocardial infarction within 3 months before the first dose of study treatment
- Patients with clinically significant preexisting cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or symptomatic congestive heart failure
- Patients with any other clinically significant medical condition which, in the opinion of the treating physician, makes it undesirable for the patient to participate in the study or which could jeopardize compliance with study requirements including, but not limited to: ongoing or active infection, significant uncontrolled hypertension, or severe psychiatric illness/social situations
- Patients with known left ventricular ejection fraction (LVEF) < 40%
- Ongoing toxicity > grade 2, other than alopecia or grade 2 peripheral neuropathy
- Patient is pregnant or nursing
Helyszínek itt: Hollandia
- Haga Hospital's-Gravenhage, HollandiaRésztvevőt keres
- Noordwest Ziekenhuisgroep StichtingAlkmaar, HollandiaRésztvevőt keres
- Ziekenhuisgroep Twente StichtingAlmelo, HollandiaRésztvevőt keres
- Meander Medisch Centrum StichtingAmersfoort, HollandiaRésztvevőt keres
- Academisch Medisch CentrumAmsterdam, HollandiaRésztvevőt keres
- Amsterdam UMC StichtingAmsterdam, HollandiaRésztvevőt keres
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingAmsterdam, HollandiaRésztvevőt keres
- OLVG StichtingAmsterdam, HollandiaRésztvevőt keres
- Gelre HospitalsApeldoorn, HollandiaRésztvevőt keres
- Rijnstate Ziekenhuis StichtingArnhem, HollandiaRésztvevőt keres
- Amphia HospitalBreda, HollandiaRésztvevőt keres
- Reinier de Graaf GroepDelft, HollandiaRésztvevőt keres
- Deventer ZiekenhuisDeventer, HollandiaRésztvevőt keres
- Ziekenhuis Nij SmellingheDrachten, HollandiaRésztvevőt keres
- Ziekenhuis Gelderse Vallei StichtingEde Gld, HollandiaRésztvevőt keres
- Máxima Medisch CentrumEindhoven, HollandiaRésztvevőt keres
- Beatrix ZiekenhuisGorinchem, HollandiaRésztvevőt keres
- Stichting Martini ZiekenhuisGroningen, HollandiaRésztvevőt keres
- Universitair Medisch Centrum GroningenGroningen, HollandiaRésztvevőt keres
- Zuyderland Medisch Centrum StichtingHeerlen, HollandiaRésztvevőt keres
- TergooiziekenhuizenHilversum, HollandiaRésztvevőt keres
- Spaarne Gasthuis StichtingHoofddorp, HollandiaRésztvevőt keres
- Treant Ziekenhuiszorg StichtingHoogeveen, HollandiaRésztvevőt keres
- Medisch Centrum Leeuwarden B.V.Leeuwarden, HollandiaRésztvevőt keres
- Leids Universitair Medisch Centrum (LUMC)Leiden, HollandiaRésztvevőt keres
- Medical Center HaaglandenLeidschendam, HollandiaRésztvevőt keres
- University Hospital MaastrichtMaastricht, HollandiaRésztvevőt keres
- Stichting Radboud Universitair Medisch CentrumNijmegen, HollandiaRésztvevőt keres
- Bravis ZiekenhuisRoosendaal, HollandiaRésztvevőt keres
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, HollandiaRésztvevőt keres
- Sint Franciscus Vlietland Groep StichtingSchiedam, HollandiaRésztvevőt keres
- St. Elisabeth Hospital TilburgTilburg, HollandiaRésztvevőt keres
- St Antonius ZiekenhuisUtrecht, HollandiaRésztvevőt keres
- Universitair Medisch Centrum UtrechtUtrecht, HollandiaRésztvevőt keres
- Stichting Viecuri Medisch Centrum voor Noord-LimburgVenlo, HollandiaRésztvevőt keres
- Isala Klinieken StichtingZwolle, HollandiaRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
1) To describe the anti-tumor activity and toxicity of commercially available, targeted anti-cancer drugs used for treatment of patients with an advanced solid tumor, multiple myeloma, non-Hodgkin lymphoma or T-cell prolymphocytic leukemia that harbors a genomic- or protein expression variant known to be a drug target or to predict sensitivity to a drug. 2) To facilitate patient access to commercially available, targeted anti-cancer drugs of potential efficacy for treatment of an advanced solid tumor, multiple myeloma, non-Hodgkin lymphoma or T-cell prolymphocytic leukemia that harbors a genomic or protein expression variant known to be a drug target or to predict sensitivity to a drug.
A vizsgálat 30 csoportja
- PanitumumabA vizsgált kezelés
Panitumumab for patients with a molecular tumor profile that can potentially be targeted by Panitumumab.
- OlaparibA vizsgált kezelés
Olaparib for patients with a molecular tumor profile that can potentially be targeted by Olaparib.
- DabrafenibA vizsgált kezelés
Dabrafenib for patients with a molecular tumor profile that can potentially be targeted by Dabrafenib.
- NilotinibA vizsgált kezelés
Nilotinib for patients with a molecular tumor profile that can potentially be targeted by nilotinib.
- TrametinibA vizsgált kezelés
Trametinib for patients with a molecular tumor profile that can potentially be targeted by trametinib.
- ErlotinibA vizsgált kezelés
Erlotinib for patients with a molecular tumor profile that can potentially be targeted by erlotinib.
- Trastuzumab & Pertuzumab (combination)A vizsgált kezelés
Trastuzumab and Pertuzumab (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Trastuzumab and Pertuzumab.
Kezelés: Trastuzumab and Pertuzumab (combination treatment)
- Vemurafenib & Cobimetinib (combination)A vizsgált kezelés
Vemurafenib and Cobimetinib (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Vemurafenib and Cobimetinib.
Kezelés: Vemurafenib and Cobimetinib (combination treatment)
- VismodegibA vizsgált kezelés
Vismodegib for patients with a molecular tumor profile that can potentially be targeted by vismodegib.
- RegorafenibA vizsgált kezelés
Regorafenib for patients with a molecular tumor profile that can potentially be targeted by regorafenib.
- NivolumabA vizsgált kezelés
Nivolumab for patients with a molecular tumor profile that can potentially be targeted by nivolumab.
- AfatinibA vizsgált kezelés
Afatinib for patients with a molecular tumor profile that can potentially be targeted by Afatinib.
- Dabrafenib & trametinib (combination)A vizsgált kezelés
Dabrafenib and trametinib (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Dabrafenib and trametinib.
Kezelés: Dabrafenib and trametinib
- RibociclibA vizsgált kezelés
Ribociclib for patients with a molecular tumor profile that can potentially be targeted by Ribociclib.
- LenvatinibA vizsgált kezelés
Lenvatinib for patients with a molecular tumor profile that can potentially be targeted by Lenvatinib.
- PembrolizumabA vizsgált kezelés
Pembrolizumab for patients with a molecular tumor profile that can potentially be targeted by Pembrolizumab.
- DurvalumabA vizsgált kezelés
Durvalumab for patients with a molecular tumor profile that can potentially be targeted by Durvalumab.
- RucaparibA vizsgált kezelés
Rucaparib for patients with a molecular tumor profile that can potentially be targeted by Rucaparib.
- AxitinibA vizsgált kezelés
Axitinib for patients with a molecular tumor profile that can potentially be targeted by Axitinib.
- PalbociclibA vizsgált kezelés
Palbociclib for patients with a molecular tumor profile that can potentially be targeted by Palbociclib.
- CrizotinibA vizsgált kezelés
Crizotinib for patients with a molecular tumor profile that can potentially be targeted by Crizotinib.
- SunitinibA vizsgált kezelés
Sunitinib for patients with a molecular tumor profile that can potentially be targeted by Sunitinib.
- CabozantinibA vizsgált kezelés
Cabozantinib for patients with a molecular tumor profile that can potentially be targeted by Cabozantinib.
- AbemaciclibA vizsgált kezelés
Abemaciclib for patients with a molecular tumor profile that can potentially be targeted by Abemaciclib.
- AlectinibA vizsgált kezelés
Alectinib for patients with a molecular tumor profile that can potentially be targeted by Alectinib.
- Atezolizumab/bevacizumabA vizsgált kezelés
Atezolizumab and bevacizumab (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Atezolizumab and bevacizumab.
Kezelés: Atezolizumab and Bevacizumab
- Ipilimumab/nivolumabA vizsgált kezelés
Ipilimumab and nivolumab (combination treatment) for patients with a molecular tumor profile that can potentially be targeted by Ipilimumab and nivolumab.
Kezelés: Ipilimumab and nivolumab
- EntrectinibA vizsgált kezelés
Entrectinib for patients with a molecular tumor profile that can potentially be targeted by entrectinib.
- TalazoparibA vizsgált kezelés
Talazoparib for patients with a molecular tumor profile that can potentially be targeted by talazoparib.
- dacomitinibA vizsgált kezelés
Dacomitinib for patients with a molecular tumor profile that can potentially be targeted by dacomitinib.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial)
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 9.
- Publikációk
- Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP).European journal of cancer (Oxford, England : 1990), 2024
- Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.BMC cancer, 2023
- Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature.Cancer chemotherapy and pharmacology, 2022
- Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma.European urology, 2022
- A regiszteradat frissítve
- 2026. augusztus 20.